On the heels of the NIH-supported Expanded Access Program (EAP) for Convalescent Plasma, a secondary antibody testing modality has been developed as part of the Antibody Everybody initiative powered by Streamline Verify. Researchers are eagerly seeking data to know and study if the same individuals who tested positive for antibodies in the first round, still have antibodies months later.

The “follow-on” study took place last week and used an identical process of the EAP and recruited 200 of the same individuals used in the first study. This observational study will help to advance the science of COVID19 medical research.

This secondary initiative was born out of the first round NIH-supported Expanded Access Program (EAP) for Convalescent Plasma , a program in which more than 10,000 COVID-19 patients have received plasma transfusions. To date, a large number of convalescent plasma donations have come from members of community hit hard by the pandemic . A coalition of partners that formed the Antibody Everybody initiative organized hundreds of plasma donations at blood banks and outdoor testing sites from the NY-NJ Metro area to Delaware.

In the past few months, the partners conducted complex, awe-inspiring logistics in this rapid acquisition and processing of the largest batch of specimens collected to date which arrived in Minnesota in May 2020.

To combat the pandemic globally, it will take many, multi-faceted scientifically proven initiatives. Streamline Verify is honored to play a role in advancing science and partnering with experts in finding proven COVID-19 solutions.